QTRX

Quanterix Corp

Add to Watchlist

Advanced Chart

5.370

-0.14(-2.541%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.6292

Open

5.590

VWAP

5.42

Vol

482.18K

Mkt Cap

248.08M

Low

5.350

Amount

2.61M

EV/EBITDA(TTM)

Total Shares

38.27M

-18.79M

EV/OCF(TTM)

P/S(TTM)

1.52

Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

30.30M

-11.87%

34.17M

-4.6%

36.43M

+3.62%

Estimates Revision

The market is revising Downward the revenue expectations for Quanterix Corporation (QTRX) for FY2025, with the revenue forecasts being adjusted by -8.1% over the past three months. During the same period, the stock price has changed by 9.82%.

Revenue Estimates for FY2025

Revise Downward

-8.1%

In Past 3 Month

Stock Price

Go Up

+9.82%

In Past 3 Month

3 Analyst Rating

76.91% Upside

Wall Street analysts forecast QTRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 9.50 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

76.91% Upside

Current: 5.370

Low

7.00

Averages

9.50

High

12.00

76.91% Upside

Current: 5.370

Low

7.00

Averages

9.50

High

12.00

Nephron Research

Buy

Hold

downgrade

2025-07-09

Reason

Nephron Research

Price Target

2025-07-09

downgrade

Buy

Hold

Reason

Nephron Research downgraded Quanterix to Hold from Buy with an $8 price target.

Morgan Stanley

Equal Weight

downgrade

2025-06-02

Reason

Morgan Stanley

Price Target

2025-06-02

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Akoya Biosciences (AKYA) to $1.14 from $3 and keeps an Equal Weight rating on the shares. The firm is updating its model for Akoya's Q1 results and the amended merger agreement proposed by Quanterix (QTRX), the analyst tells investors.

Scotiabank

Sung Nam

Buy

Maintains

$28 → $18

2025-03-25

Reason

Scotiabank

Sung Nam

Price Target

$28 → $18

2025-03-25

Maintains

Buy

Reason

Scotiabank analyst Sung Ji Nam lowered the firm's price target on Quanterix to $18 from $28 and keeps an Outperform rating on the shares. Despite the relatively stronger revenue growth performance compared to its peer group, the company's shares underperformed over the last year, the analyst tells investors. While the firm thinks the operating synergy targets are reasonable, it is less certain about the top line growth potential.

Canaccord Genuity

Kyle Mikson

Strong Buy

Maintains

$20 → $15

2025-03-18

Reason

Canaccord Genuity

Kyle Mikson

Price Target

$20 → $15

2025-03-18

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Quanterix (QTRX) to $15 from $20 and keeps a Buy rating on the shares. The firm said they continue to viewthe company as undervalued following the company's solid performance in 4Q24. That said, they recognize negative investor sentiment on its merger with Akoya Biosciences (AKYA) may negatively impact share price performance going forward.

TD Cowen

Daniel Brennan

Hold

Maintains

$14 → $16

2024-11-13

Reason

TD Cowen

Daniel Brennan

Price Target

$14 → $16

2024-11-13

Maintains

Hold

Reason

TD Cowen raised the firm's price target on Quanterix to $16 from $13.50 and keeps a Hold rating on the shares. The firm said Q3 results beat with sales and its Alzheimer's blood testing sales are nascent, though drivers are coming into place for traction in 2025 and beyond.

Scotiabank

Sung Nam

Buy

Maintains

$32 → $28

2024-08-12

Reason

Scotiabank

Sung Nam

Price Target

$32 → $28

2024-08-12

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Quanterix Corp (QTRX.O) is -3.99, compared to its 5-year average forward P/E of -18.38. For a more detailed relative valuation and DCF analysis to assess Quanterix Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.38

Current PE

-3.99

Overvalued PE

-7.58

Undervalued PE

-29.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.09

Current EV/EBITDA

0.37

Overvalued EV/EBITDA

-0.80

Undervalued EV/EBITDA

-27.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

8.62

Current PS

1.52

Overvalued PS

14.87

Undervalued PS

2.37

Financials

Annual

Quarterly

FY2025Q1

YoY :

-5.40%

30.33M

Total Revenue

FY2025Q1

YoY :

+73.95%

-26.37M

Operating Profit

FY2025Q1

YoY :

+83.68%

-20.50M

Net Income after Tax

FY2025Q1

YoY :

+82.76%

-0.53

EPS - Diluted

FY2025Q1

YoY :

-26.73%

-15.14M

Free Cash Flow

FY2025Q1

YoY :

-6.43%

54.12

Gross Profit Margin - %

FY2025Q1

YoY :

-9.15%

-24.32

FCF Margin - %

FY2025Q1

YoY :

+94.20%

-67.60

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 215.62% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

2.6M

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

831.7K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 215.62% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

2.6M

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

831.7K

USD

Months

QTRX News & Events

Events Timeline

2025-06-23 (ET)

2025-06-23

07:44:34

Quanterix HD-X Simoa gets Class 1 Medical Device registration in South Korea

2025-06-11 (ET)

2025-06-11

08:05:48

Kent Lake condemns Quanterix's failure to schedule its 2025 Annual Meeting

2025-05-12 (ET)

2025-05-12

16:04:10

Quanterix cuts FY25 revenue view to $120M-$130M from $140M-$146M

News

8.5

07-09NASDAQ.COM

Quanterix Completes Akoya Acquisition, Expands Biomarker Reach To $5 Bln Market

9.0

06-23Newsfilter

Quanterix Expands Reach with IVD and Large Reference Labs

9.0

06-11PRnewswire

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

People Also Watch

Southern States Bancshares Inc

USD

-0.08%

HRTG

Heritage Insurance Holdings Inc

Barnes & Noble Education Inc

Haverty Furniture Companies Inc

Seaport Entertainment Group Inc

FAQ

What is Quanterix Corp (QTRX) stock price today?

The current price of QTRX is 5.37 USD — it has decreased -2.54 % in the last trading day.

QTRX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

QTRX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Quanterix Corp (QTRX) stock price today?

What is Quanterix Corp (QTRX)'s business?

What is the price predicton of QTRX Stock?

What is Quanterix Corp (QTRX)'s revenue for the last quarter?

What is Quanterix Corp (QTRX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Quanterix Corp (QTRX)'s fundamentals?

How many employees does Quanterix Corp (QTRX). have?

What is Quanterix Corp (QTRX) market cap?